GLP-1 drugs cost supermarkets a billion
People using GLP-1 drugs for weight loss eat measurably less. In the United Kingdom, that already wiped nearly a billion dollars from annual grocery spending last year.
GLP-1 agonists are drugs originally developed for diabetes that are now widely used for obesity. Well-known examples include Ozempic and Mounjaro. They work partly by suppressing hunger and slowing gastric emptying. A large study by market research firm Worldpanel by Numerator now shows just how visible that effect is in shopping behaviour.
Households with at least one GLP-1 user bought 299 million fewer food items in the year after starting the medication in the UK. Users reported fewer cravings and less desire for snacks like chocolate and crisps. According to Bloomberg News, that erased nearly a billion dollars from annual supermarket revenues.
Use has almost tripled in two years
What makes this effect so large is the scale. GLP-1 use in the UK has nearly tripled in two years: from 2.3% of households in 2024 to 6.3% now. The researchers at Worldpanel describe a direct correlation between the time of adoption and the drop in purchases, though causal claims cannot be made from observational data alone.
Meanwhile, large US employers are reporting growing pressure on GLP-1 drug coverage. Around 10% of employers who currently cover the drugs for weight loss are considering dropping that coverage in 2027, citing rapidly rising costs as more people take the medications.
Longevity relevance: beyond weight loss
For longevity research, GLP-1 agonists are interesting beyond their effect on weight. Studies are underway into potential protective effects on the heart, kidneys and brain. The societal and economic scale of use is growing fast enough that the broader consequences have barely been thought through yet.